{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:10:01Z","timestamp":1793841001309,"version":"4.6.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for locally advanced non-small-cell lung cancer (LA-NSCLC), whereas responses to anti-programmed cell death-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) are heterogeneous. Though consolidation ICI following concurrent chemoradiotherapy (cCRT) improves survival of NSCLC, this regimen is challenging for patients with bulky tumors due to excessive target volumes and radiation-resistant hypoxia during upfront cCRT, leading to higher risk of pneumonitis and inferior local-regional control. Recent trials have demonstrated neoadjuvant ICI brought greater benefit to stage III than stage I-II NSCLC. Our previous study also supported the therapeutic advantage of 2-cycle induction ICI for patients with bulky unresectable stage III NSCLC. In the context of induction immunotherapy, radiotherapy is more likely to exert immune synergistic effects, reverse anti-PD-1 resistance, and activate abscopal immune responses. Prospective trials to determine the efficacy and safety of induction ICI for bulky LA-NSCLC are necessary.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This randomized, open-label, two-arm phase II study aims to explore whether 2 cycles of induction anti-PD-1 toripalimab plus chemotherapy can improve progression-free survival (PFS) in bulky LA-NSCLC. Bulky tumors are defined as primary lesion \u22655 cm in greatest dimension or metastatic lymph nodes \u22652 cm in shortest diameter. A total of 50 patients with bulky unresectable stage III NSCLC will be recruited and 1:1 randomized into the experimental arm: 2-cycle induction PD-1 inhibitor toripalimab plus chemotherapy followed by cCRT and consolidation toripalimab; or control arm: 2-cycle induction chemotherapy followed by cCRT and consolidation toripalimab. Patients are stratified by pathology (squamous versus non-squamous). The primary endpoint is PFS. Secondary endpoints are overall survival, overall response rate, disease control rate, duration of response, and incidence of adverse events. Exploratory analyses include PD-L1 expression and liquid biopsy-based biomarker testing, tumor microenvironment profiling at single-cell levels, and quality-of-life assessments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The InTRist study is the first randomized phase II trial to investigate the feasibility of induction anti-PD-1 toripalimab plus chemotherapy followed by cCRT and consolidation toripalimab in bulky LA-NSCLC, providing novel evidence for the synergistic strategy combining anti-PD-1 blockade with radiotherapy to prolong immunotherapy benefits, overcome resistance, and enhance abscopal immune response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:uri>ClinicalTrials.gov<\/jats:uri>, identifier NCT05888402.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1341584","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T04:17:33Z","timestamp":1705292253000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study)"],"prefix":"10.3389","volume":"14","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jima","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinfu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2022.09.004","article-title":"Etiology of lung cancer: Evidence from epidemiologic studies","volume":"2","author":"Zou","year":"2022","journal-title":"J Natl Cancer Center"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Auperin","year":"2010","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2022.07.004","article-title":"Lung cancer incidence and mortality in China: Updated statistics and an overview of temporal trends from 2000 to 2016","volume":"2","author":"Zheng","year":"2022","journal-title":"J Natl Cancer Center"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.06.034","article-title":"Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer","volume":"70","author":"Werner-Wasik","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.02.012","article-title":"Tumor oxygenation by myo-inositol trispyrophosphate enhances radiation response","volume":"110","author":"Grgic","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B9","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ijrobp.2022.12.042","article-title":"Induction immune checkpoint inhibitors and chemotherapy before definitive chemoradiation therapy for patients with bulky unresectable stage III non-small cell lung cancer","volume":"116","author":"Wang","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.10.014","article-title":"When constrained by constraints: thinking outside of the box in both technology and biology","volume":"110","author":"Chang","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.12.150","article-title":"Real-world safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage III non-small cell lung cancer: A systematic review and meta-analysis","volume":"112","author":"Wang","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00630-6","article-title":"Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"425126","DOI":"10.1200\/JCO.2023.41.36_suppl.425126","article-title":"Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II\/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study","volume":"41","author":"Wu","year":"2023","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"1996000","DOI":"10.1080\/2162402X.2021.1996000","article-title":"Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer","volume":"10","author":"Zhao","year":"2021","journal-title":"Oncoimmunology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S984","DOI":"10.1016\/j.annonc.2022.07.1081","article-title":"955P Updated event-free survival of neoadjuvant toripalimab with chemotherapy for resectable stage III NSCLC (NeoTAP01 study)","volume":"33","author":"Zhao","year":"2022","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00727","article-title":"Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: A multicenter randomized phase III trial (CHOICE-01)","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1186\/s12916-022-02696-4","article-title":"Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial","volume":"20","author":"Zhu","year":"2022","journal-title":"BMC Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1135140","article-title":"Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer","volume":"13","author":"Tao","year":"2023","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J Natl Compr Cancer Network JNCCN"},{"key":"B21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/978-3-319-62642-0_15","article-title":"Non-small cell lung cancer","volume-title":"Handbook of evidence-based radiation oncology","author":"Wahl","year":"2018"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0982","article-title":"Effect of midtreatment PET\/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: A phase 2 clinical trial","volume":"3","author":"Kong","year":"2017","journal-title":"JAMA Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)90535-5","article-title":"The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life","author":"Bergman","year":"1994","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1020937","article-title":"The impact of the COVID-19 pandemic on palliative care practice: A survey of clinical oncologists","volume":"10","author":"Wang","year":"2022","journal-title":"Front Public Health"},{"key":"B27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic - implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.07.021","article-title":"OA02.05 Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study","volume":"17","author":"Wu","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1281888","article-title":"Efficacy and safety of definitive chemoradiotherapy with or without induction immune checkpoint inhibitors in patients with stage III non-small cell lung cancer","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-1379","article-title":"Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)","volume":"132","author":"Robinson","year":"2007","journal-title":"Chest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyr188","article-title":"Differences between squamous cell carcinoma and adenocarcinoma of the lung: are adenocarcinoma and squamous cell carcinoma prognostically equal","volume":"42","author":"Kawase","year":"2012","journal-title":"Japanese J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1378\/chest.118.1.123","article-title":"Induction therapy for non-small cell lung cancer with involved mediastinal nodes in multiple stations","volume":"118","author":"Okada","year":"2000","journal-title":"Chest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.788856","article-title":"Case report: first case of consolidation immunotherapy after definitive chemoradiotherapy in mediastinal lymph node metastatic sarcomatoid carcinoma","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s0169-5002(00)00128-8","article-title":"Prognostic impact of bulky mediastinal lymph nodes (N2>2.5 cm) in patients with locally advanced non-small-cell lung cancer (LA-NSCLC) treated with platinum-based induction chemotherapy","volume":"30","author":"Maurel","year":"2000","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.annonc.2022.06.013","article-title":"Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches","volume":"33","author":"Cortiula","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1341584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T04:17:37Z","timestamp":1705292257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1341584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2023.1341584"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1341584","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]},"article-number":"1341584"}}